PMID- 35059267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220811
IS  - 2190-1678 (Print)
IS  - 2190-1686 (Electronic)
IS  - 2190-1678 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Jan
TI  - Dupilumab-related type 1 diabetes in a patient with atopic dermatitis: a case 
      report.
PG  - 300-303
LID - 10.1007/s13340-021-00526-1 [doi]
AB  - Dupilumab, a humanized monoclonal antibody that inhibits both interleukin (IL)-4 
      and IL-13 signals, is used as a treatment for a variety of allergic diseases 
      including atopic dermatitis. We experienced a case of dupilumab-related type 1 
      diabetes in a patient with atopic dermatitis. An 18-year-old female presented 
      with thirst and polydipsia seven months after initiating dupilumab therapy for 
      atopic dermatitis and was found to have marked hyperglycemia with ketosis. She 
      was positive for anti-glutamic acid decarboxylase antibody, leading to the 
      diagnosis of type 1 diabetes. She carried human leukocyte antigen (HLA) genes 
      associated with type 1 diabetes. Most type 1 diabetes is considered a T-helper 
      (Th) 1 type autoimmune disease, whereas IL-4 and IL-13, which are Th2 cytokines, 
      play inhibitory roles in the pathogenesis of type 1 diabetes. This case implies 
      that dupilumab might contribute to the development of type 1 diabetes in 
      individuals with a genetic background of type 1 diabetes via relative Th1 
      dominance. To our knowledge, this is the first case of the development of type 1 
      diabetes during dupilumab therapy. As dupilumab therapy might accelerate the 
      development of type 1 diabetes, it is important to note cases like this case to 
      clarify the pathogenic mechanisms underlying dupilumab-related type 1 diabetes.
CI  - (c) The Japan Diabetes Society 2021.
FAU - Kurokawa, Yasuharu
AU  - Kurokawa Y
AD  - Division of Diabetes, Endocrinology and Metabolism, Department of Internal 
      Medicine, Federation of National Public Service Personnel Mutual Aid Associations 
      Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo 190-8531 Japan. GRID: 
      grid.416823.a
FAU - Oikawa, Yoichi
AU  - Oikawa Y
AD  - Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical 
      University, Saitama, 350-0495 Japan. GRID: grid.410802.f. ISNI: 0000 0001 2216 
      2631
FAU - Shimada, Akira
AU  - Shimada A
AD  - Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical 
      University, Saitama, 350-0495 Japan. GRID: grid.410802.f. ISNI: 0000 0001 2216 
      2631
FAU - Yajima, Ken
AU  - Yajima K
AUID- ORCID: 0000-0003-0175-5483
AD  - Division of Diabetes, Endocrinology and Metabolism, Department of Internal 
      Medicine, Federation of National Public Service Personnel Mutual Aid Associations 
      Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo 190-8531 Japan. GRID: 
      grid.416823.a
LA  - eng
PT  - Case Reports
DEP - 20210810
PL  - Japan
TA  - Diabetol Int
JT  - Diabetology international
JID - 101553224
PMC - PMC8733041
OTO - NOTNLM
OT  - Adolescent
OT  - Autoimmune disease
OT  - Dupilumab
OT  - Human leukocyte antigen
OT  - Type 1 diabetes
COIS- Conflict of interest A.S. received lecture fees from Novo Nordisk Pharma Ltd., 
      Tokyo, Japan, and Sanofi K.K., Tokyo, Japan. Other authors have no potential 
      conflicts of interest relevant to this article.
EDAT- 2022/01/22 06:00
MHDA- 2022/01/22 06:01
PMCR- 2022/08/10
CRDT- 2022/01/21 06:21
PHST- 2021/05/20 00:00 [received]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2022/01/21 06:21 [entrez]
PHST- 2022/01/22 06:00 [pubmed]
PHST- 2022/01/22 06:01 [medline]
PHST- 2022/08/10 00:00 [pmc-release]
AID - 526 [pii]
AID - 10.1007/s13340-021-00526-1 [doi]
PST - epublish
SO  - Diabetol Int. 2021 Aug 10;13(1):300-303. doi: 10.1007/s13340-021-00526-1. 
      eCollection 2022 Jan.